文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

在系统性红斑狼疮和基于免疫抑制细胞的新疗法中,HELIOS 作为一种潜在的生物标志物。

Helios as a Potential Biomarker in Systemic Lupus Erythematosus and New Therapies Based on Immunosuppressive Cells.

机构信息

Department of Immunology and Oncology and NanoBiomedicine Initiative, Centro Nacional de Biotecnología (CNB-CSIC), 28049 Madrid, Spain.

Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy, IdiPAZ, Hospital Universitario La Paz, 28049 Madrid, Spain.

出版信息

Int J Mol Sci. 2023 Dec 29;25(1):452. doi: 10.3390/ijms25010452.


DOI:10.3390/ijms25010452
PMID:38203623
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10778776/
Abstract

The Helios protein (encoded by the gene) is a member of the Ikaros transcription family and it has recently been proposed as a promising biomarker for systemic lupus erythematosus (SLE) disease progression in both mouse models and patients. Helios is beginning to be studied extensively for its influence on the T regulatory (Treg) compartment, both CD4 Tregs and KIR/Ly49 CD8 Tregs, with alterations to the number and function of these cells correlated to the autoimmune phenomenon. This review analyzes the most recent research on Helios expression in relation to the main immune cell populations and its role in SLE immune homeostasis, specifically focusing on the interaction between T cells and tolerogenic dendritic cells (tolDCs). This information could be potentially useful in the design of new therapies, with a particular focus on transfer therapies using immunosuppressive cells. Finally, we will discuss the possibility of using nanotechnology for magnetic targeting to overcome some of the obstacles related to these therapeutic approaches.

摘要

Helios 蛋白(由 基因编码)是 Ikaros 转录家族的成员,最近有人提出它是系统性红斑狼疮(SLE)疾病进展的有前途的生物标志物,无论是在小鼠模型还是患者中。Helios 因其对 T 调节(Treg)区的影响而开始被广泛研究,包括 CD4 Tregs 和 KIR/Ly49 CD8 Tregs,这些细胞的数量和功能的改变与自身免疫现象相关。这篇综述分析了 Helios 表达与主要免疫细胞群的关系及其在 SLE 免疫稳态中的作用的最新研究,特别关注了 T 细胞与耐受原性树突状细胞(tolDCs)之间的相互作用。这些信息对于设计新的治疗方法可能非常有用,特别是侧重于使用免疫抑制细胞的转移治疗。最后,我们将讨论使用纳米技术进行磁性靶向的可能性,以克服与这些治疗方法相关的一些障碍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a863/10778776/78b480ddde66/ijms-25-00452-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a863/10778776/fe973a09976e/ijms-25-00452-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a863/10778776/82d18fe97f15/ijms-25-00452-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a863/10778776/c443838be24d/ijms-25-00452-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a863/10778776/cbb53cb5c935/ijms-25-00452-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a863/10778776/b580d9ae0ddd/ijms-25-00452-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a863/10778776/78b480ddde66/ijms-25-00452-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a863/10778776/fe973a09976e/ijms-25-00452-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a863/10778776/82d18fe97f15/ijms-25-00452-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a863/10778776/c443838be24d/ijms-25-00452-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a863/10778776/cbb53cb5c935/ijms-25-00452-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a863/10778776/b580d9ae0ddd/ijms-25-00452-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a863/10778776/78b480ddde66/ijms-25-00452-g006.jpg

相似文献

[1]
Helios as a Potential Biomarker in Systemic Lupus Erythematosus and New Therapies Based on Immunosuppressive Cells.

Int J Mol Sci. 2023-12-29

[2]
Helios Expression Is Downregulated on CD8 Treg in Two Mouse Models of Lupus During Disease Progression.

Front Immunol. 2022

[3]
Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus.

Ann Rheum Dis. 2012-12-21

[4]
Regulatory T cells in systemic lupus erythematosus.

Eur J Immunol. 2015-2

[5]
Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp Risk Allele Drive the Expansion of FOXP3 Regulatory T Cells and PD-1 Expression.

Front Immunol. 2019-11-8

[6]
Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseases.

Immunotherapy. 2009-5

[7]
Current Paradigms of Tolerogenic Dendritic Cells and Clinical Implications for Systemic Lupus Erythematosus.

Cells. 2019-10-21

[8]
Autologous tolerogenic dendritic cells derived from monocytes of systemic lupus erythematosus patients and healthy donors show a stable and immunosuppressive phenotype.

Immunology. 2017-12

[9]
Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice.

Immunology. 2019-10-7

[10]
Engineered PD-1/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell/Treg balance and alleviate systemic lupus erythematosus.

Biomaterials. 2022-6

引用本文的文献

[1]
Natural Killer Cells and Cytotoxic T Cells: Complementary Partners against Microorganisms and Cancer.

Microorganisms. 2024-1-22

本文引用的文献

[1]
Human T cells loaded with superparamagnetic iron oxide nanoparticles retain antigen-specific TCR functionality.

Front Immunol. 2023

[2]
Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration.

Immunother Adv. 2023-7-18

[3]
Flow Cytometry: The Next Revolution.

Cells. 2023-7-17

[4]
Co-expression of Foxp3 and Helios facilitates the identification of human T regulatory cells in health and disease.

Front Immunol. 2023

[5]
A review on nanoparticles: characteristics, synthesis, applications, and challenges.

Front Microbiol. 2023-4-17

[6]
Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.

Int J Mol Sci. 2023-3-31

[7]
Application of Machine Learning Models in Systemic Lupus Erythematosus.

Int J Mol Sci. 2023-2-24

[8]
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial.

Lancet Rheumatol. 2022-11-28

[9]
The emerging role of regulatory cell-based therapy in autoimmune disease.

Front Immunol. 2022

[10]
The role of tolerogenic dendritic cells in systematic lupus erythematosus progression and remission.

Int Immunopharmacol. 2023-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索